Conversion of Loan Notes & TVR (Replacement)

This announcement amends and replaces the announcement made at 14:36 on 10 October 2014 under RNS Number: 0322U. The nominal value of the ordinary shares is GBP0.01 each. All other details remain unchanged. The full amended text is shown below.

Cyprotex PLC

("Cyprotex" or "the Company")

Conversion of Loan Notes & Total Voting Rights

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that it has issued 8,643 new ordinary shares of GBP0.01 each ("new Ordinary Shares") pursuant to the conversion of Convertible Loan Notes.

The issue of these new Ordinary shares is subject to the new Ordinary Shares being admitted to trading on AIM, application for which has been made. Trading in the new Ordinary Shares, which will rank pari passu in all respects with the existing ordinary shares, is expected to commence on 16 October 2014.

Total Voting Rights

Following the issue of the 8,643 new Ordinary Shares on 16 October 2014, the Company will have a total of 22,442,699 Ordinary Shares in issue and one voting right per Ordinary Share.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

The above information is provided by the Company in accordance with its obligations under the FSA's Disclosure and Transparency Rules.

For further information:

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com